Peter Gøtzsche

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/3405173/publications.pdf

Version: 2025-02-01

235 peer-reviewed articles	96,254 peer-reviewed citations	26474 58 peer-reviewed h-index	408697 4.65 score
296 documents	103083 doc citations	22595 65 h-index	247637 citing authors

#	Article	IF	Citations
1	Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in Relation to Time in Therapeutic Range: An Analysis of US Food and Drug Administration Regulatory Data. Circulation: Cardiovascular Quality and Outcomes, 2025, 18, .	2.8	0
2	Interventions to help patients withdraw from depression drugs: A systematic review. International Journal of Risk and Safety in Medicine, 2024, 35, 103-116.	0.4	9
3	Systematic violations of patients' rights and safety: forced medication of a cohort of 30 patients in Alaska. Psychosis, 2023, 15, 145-154.	0.4	1
4	Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents. Journal of Clinical Epidemiology, 2022, 143, 242-253.	2.5	3
5	Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane Library, 2022, 2022, .	1.7	14
6	Made in China: the coronavirus that killed millions of people. Indian Journal of Medical Ethics, 2022, 7, 254-254.	0.2	4
7	Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents: author's reply. Journal of Clinical Epidemiology, 2022, 145, 183-184.	2.5	1
8	Restoring the two pivotal fluoxetine trials in children and adolescents with depression. International Journal of Risk and Safety in Medicine, 2022, 33, 385-408.	0.4	8
9	House dust mite control measures for asthma. The Cochrane Library, 2021, 2021, .	1.7	26
10	Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2021, 2021, .	1.7	12
11	Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants. International Journal of Risk and Safety in Medicine, 2021, 32, 87-99.	0.4	5
12	Joint study led by International Food Policy Research Institute (IFPRI) puts meat-eating women's lives at risk. Indian Journal of Medical Ethics, 2021, 06, 81-82.	0.2	0
13	Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs. Research Integrity and Peer Review, 2021, 6, .	3.6	7
14	Are investigators' access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials. BMC Medical Ethics, 2021, 22, .	1.7	3
15	Long-term use of antipsychotics and antidepressants is not evidence-based. International Journal of Risk and Safety in Medicine, 2020, 31, 37-42.	0.4	8
16	Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence. Npj Vaccines, 2020, 5, .	3.9	3
17	Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. Systematic Reviews, 2020, 9, .	3.7	31
18	Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. Systematic Reviews, 2020, 9, .	3.7	5

#	Article	IF	Citations
19	Presentation of benefits and harms of antidepressants on websites: A cross-sectional study. International Journal of Risk and Safety in Medicine, 2020, 31, 53-65.	0.4	19
20	Title is missing!. , 2020, .		2
21	What have antidepressants been tested for? A systematic review. International Journal of Risk and Safety in Medicine, 2020, 31, 157-163.	0.4	6
22	Systematic violations of patients' rights and safety: Forced medication of a cohort of 30 patients. Indian Journal of Medical Ethics, 2020, 05, 312-318.	0.2	4
23	Title is missing!. , 2020, .		0
24	Effect of lithium on suicide and mortality in mood disorders: A systematic review. International Journal of Risk and Safety in Medicine, 2019, 30, 155-166.	0.4	13
25	Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. International Journal of Risk and Safety in Medicine, 2019, 30, 217-232.	0.4	15
26	General health checks in adults for reducing morbidity and mortality from disease. The Cochrane Library, 2019, 2019, .	1.7	119
27	Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. International Journal of Risk and Safety in Medicine, 2019, 30, 193-201.	0.4	8
28	Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. International Journal of Risk and Safety in Medicine, 2019, 30, 59-71.	0.4	10
29	Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. BMJ Open, 2019, 9, e026661.	1.2	10
30	Screening for reducing morbidity and mortality in malignant melanoma. The Cochrane Library, 2019, 2019, .	1.7	62
31	What is the moral collapse in the Cochrane Collaboration about?. Indian Journal of Medical Ethics, 2019, IV, 303-309.	0.2	1
32	Redactions in protocols for drug trials: what industry sponsors concealed. Journal of the Royal Society of Medicine, 2018, 111, 136-141.	0.8	12
33	A totally new system is needed for drug research and development. European Journal of Clinical Investigation, 2018, 48, .	2.2	5
34	Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. Systematic Reviews, 2018, 7, .	3.7	24
35	Routine versus selective antifungal administration for control of fungal infections in patients with cancer. The Cochrane Library, 2017, 2017, .	1.7	15
36	Nystatin prophylaxis and treatment in severely immunodepressed patients. The Cochrane Library, 2017, 2017, .	1.7	30

#	Article	IF	Citations
37	Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. The Cochrane Library, 2017, 2017, .	1.7	10
38	Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. The Cochrane Library, 2017, 2017, .	1.7	16
39	Breast Cancer Screening in Denmark. Annals of Internal Medicine, 2017, 166, 313-323.	7.3	114
40	Patients should have free and immediate access to all information related to clinical trials. BMJ: British Medical Journal, 2017, , j1221.	0.1	1
41	Breast Cancer Screening in Denmark. Annals of Internal Medicine, 2017, 167, 524.	7.3	5
42	Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. Journal of the Royal Society of Medicine, 2017, 110, 404-410.	0.8	72
43	The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evidence-Based Medicine, 2017, 22, 143-147.	0.8	18
44	The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. Journal of Clinical Epidemiology, 2017, 91, 129-136.	2.5	18
45	Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. Cmaj, 2017, 189, E194-E203.	0.8	70
46	Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. International Journal of Risk and Safety in Medicine, 2017, 29, 107-124.	0.4	8
47	Hvad ved vi om sikkerheden af HPV-vaccinerne?. Tidsskrift for Den Norske Laegeforening, 2017, 137, 11-12.	0.1	1
48	Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis. PLoS Medicine, 2016, 13, e1002101.	4.6	62
49	Author's reply to Dubicka and colleagues and Stone. BMJ, The, 2016, , i915.	0.2	1
50	Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. The Cochrane Library, 2016, 2016, .	1.7	47
51	Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. Journal of the Royal Society of Medicine, 2016, 109, 381-392.	0.8	48
52	Screening with urinary dipsticks for reducing morbidity and mortality. The Cochrane Library, 2015, 2015, .	1.7	21
53	Under-reporting of conflicts of interest among trialists: a cross-sectional study. Journal of the Royal Society of Medicine, 2015, 108, 101-107.	0.8	42
54	Does long term use of psychiatric drugs cause more harm than good?. BMJ, The, 2015, 350, h2435-h2435.	0.2	75

#	Article	IF	Citations
55	Influence of mammography screening on use of mastectomies in Denmark. Acta Oncológica, 2015, 54, 133-134.	1.7	3
56	Author's reply to Tovey and colleagues. BMJ, The, 2015, 350, h2955-h2955.	0.2	1
57	Mammography screening is harmful and should be abandoned. Journal of the Royal Society of Medicine, 2015, 108, 341-345.	0.8	42
58	Comment on “Our prescription drugs kill us in large numbers”. Author's reply. Polish Archives of Internal Medicine, 2015, 125, 106-107.	0.2	0
59	Comparison of Results from Different Imputation Techniques for Missing Data from an Anti-Obesity Drug Trial. PLoS ONE, 2014, 9, e111964.	1.5	38
60	"Human guinea pig" asks for animal studies. BMJ, The, 2014, 349, g6714-g6714.	0.2	7
61	Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. BMJ, The, 2014, 348, g3555-g3555.	0.2	11
62	Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ, The, 2014, 348, g3510-g3510.	0.2	60
63	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. International Journal of Surgery, 2014, 12, 1500-1524.	4.0	2,738
64	Study of study of changes in antidepressant use after FDA warnings is not reliable. BMJ, The, 2014, 349, g5623-g5623.	0.2	1
65	Muscular adverse effects are common with statins. BMJ, The, 2014, 348, g3724-g3724.	0.2	3
66	Increasing value and reducing waste: addressing inaccessible research. Lancet, The, 2014, 383, 257-266.	46.9	797
67	Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. BMJ, The, 2014, 349, g4790-g4790.	0.2	1
68	Our prescription drugs kill us in large numbers. Polish Archives of Internal Medicine, 2014, 124, 628-634.	0.2	16
69	Re: Et korstog mot legemiddelindustrien. Tidsskrift for Den Norske Laegeforening, 2014, 134, 2126-2127.	0.1	0
70	Przepisywane leki przyczyną zgonu rzeszy pacjentów. Polish Archives of Internal Medicine, 2014, 124, 750-756.	0.2	0
71	Strategies for obtaining unpublished drug trial data: a qualitative interview study. Systematic Reviews, 2013, 2, .	3.7	24
72	Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Medical Ethics, 2013, 14, .	1.7	84

#	Article	IF	Citations
73	Developing a new drug costs less than $100m, not $900m. BMJ, The, 2013, 346, f398-f398.	0.2	2
74	Screening for breast cancer with mammography. The Cochrane Library, 2013, 2013, .	1.7	818
75	AbbVie considers harms to be commercially confidential information: sign a petition. BMJ, The, 2013, 347, f7569-f7569.	0.2	1
76	Universal health checks should be abandoned. BMJ, The, 2013, 347, f5227-f5227.	0.2	16
77	Citations of scientific results and conflicts of interest: the case of mammography screening. Evidence-Based Medicine, 2013, 18, 83-89.	0.8	19
78	Roche continues to drag its feet on access to Tamiflu data. BMJ, The, 2013, 346, f3001-f3001.	0.2	1
79	Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ, The, 2013, 346, f2231-f2231.	0.2	43
80	General Health Checks in Adults for Reducing Morbidity and Mortality From Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2489.	14.4	41
81	SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, The, 2013, 346, e7586-e7586.	0.2	5,045
82	Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react?. International Journal of Risk and Safety in Medicine, 2013, 25, 155-168.	0.4	5
83	Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. British Journal of Cancer, 2013, 109, 2014-2019.	4.1	92
84	The Two-County Breast Screening Trial Cannot Provide a Reliable Estimate of the Effect of Breast Cancer Screening. Radiology, 2012, 262, 729-730.	6.7	3
85	General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ, The, 2012, 345, e7191-e7191.	0.2	279
86	Why does the BMJ support donations of pulse oximeters when they have no effect?. BMJ: British Medical Journal, 2012, 344, e409-e409.	0.1	1
87	Income from reprints creates a conflict of interests. BMJ, The, 2012, 345, e4970-e4970.	0.2	1
88	Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses?. BMJ, The, 2012, 345, e7031-e7031.	0.2	84
89	European governments should sue Roche and prescribers should boycott its drugs. BMJ, The, 2012, 345, e7689-e7689.	0.2	6
90	Deficiencies in proposed new EU regulation of clinical trials. BMJ, The, 2012, 345, e8522-e8522.	0.2	16

#	Article	IF	Citations
91	Big pharma often commits corporate crime, and this must be stopped. BMJ, The, 2012, 345, e8462-e8462.	0.2	17
92	CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. International Journal of Surgery, 2012, 10, 28-55.	4.0	2,075
93	Sponsors' participation in conduct and reporting of industry trials: a descriptive study. Trials, 2012, 13, .	1.1	50
94	Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review. PLoS ONE, 2012, 7, e41174.	1.5	70
95	What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction, 2012, 107, 900-908.	3.9	93
96	Regular Health Checks: Cross-Sectional Survey. PLoS ONE, 2012, 7, e33694.	1.5	10
97	Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncology, The, 2011, 12, 1118-1124.	16.1	91
98	Why we need easy access to all data from all clinical trials and how to accomplish it. Trials, 2011, 12, .	1.1	122
99	Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Medical Research Methodology, 2011, 11, .	1.7	194
100	Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ: British Medical Journal, 2011, 343, d4692-d4692.	0.1	46
101	Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. BMJ: British Medical Journal, 2011, 343, d4829-d4829.	0.1	58
102	Opening up data at the European Medicines Agency. BMJ: British Medical Journal, 2011, 342, d2686-d2686.	0.1	94
103	The Breast Screening Programme and misinforming the public. Journal of the Royal Society of Medicine, 2011, 104, 361-369.	0.8	37
104	Niels Finsen's treatment for lupus vulgaris. Journal of the Royal Society of Medicine, 2011, 104, 41-42.	0.8	38
105	UK drug regulator destroys all evidence after 15 years. BMJ: British Medical Journal, 2011, 343, d4203-d4203.	0.1	2
106	The proposed review will not be independent without NICE. BMJ: British Medical Journal, 2011, 343, d7533-d7533.	0.1	0
107	The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal, 2011, 343, d5928-d5928.	0.1	30,738
108	Time to stop mammography screening?. Cmaj, 2011, 183, 1957-1958.	0.8	38

#	Article	IF	Citations
109	Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes and Control, 2011, 23, 15-21.	1.2	62
110	Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ: British Medical Journal, 2010, 341, c3920-c3920.	0.1	343
111	The Background Review for the USPSTF Recommendation on Screening for Breast Cancer. Annals of Internal Medicine, 2010, 152, 538.	7.3	4
112	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ: British Medical Journal, 2010, 340, c869-c869.	0.1	6,635
113	Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. BMJ: British Medical Journal, 2010, 341, c3926-c3926.	0.1	27
114	Acupuncture Treatment for Pain: Systematic Review of Randomised Clinical Trials with Acupuncture, Placebo Acupuncture, and no Acupuncture Groups. Deutsche Zeitschrift Für Akupunktur, 2010, 53, 40-41.	0.0	2
115	Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ: British Medical Journal, 2010, 341, c3653-c3653.	0.1	52
116	Breast screening: why estimates differ by a factor of 20-25. Journal of Medical Screening, 2010, 17, 158-159.	1.2	8
117	Who evaluates public health programmes? A review of the NHS Breast Screening Programme. Journal of the Royal Society of Medicine, 2010, 103, 14-20.	0.8	17
118	Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study. PLoS Medicine, 2010, 7, e1000354.	4.6	109
119	Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ: British Medical Journal, 2010, 340, c1241-c1241.	0.1	172
120	Sleep apnoea: from person to patient, and back again. BMJ: British Medical Journal, 2010, 340, c360-c360.	0.1	1
121	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology, 2010, 63, e1-e37.	2.5	1,711
122	Still awaiting screening facts. BMJ: British Medical Journal, 2010, 341, c6152-c6152.	0.1	17
123	The benefits and harms of screening for cancer with a focus on breast screening. Polish Archives of Internal Medicine, 2010, 120, 89-94.	0.2	47
124	What Should Be Done To Tackle Ghostwriting in the Medical Literature?. PLoS Medicine, 2009, 6, e1000023.	4.6	96
125	Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ: British Medical Journal, 2009, 339, b2587-b2587.	0.1	424
126	Estimation of lead time and overdiagnosis in breast cancer screening. British Journal of Cancer, 2009, 100, 219-219.	4.1	18

#	Article	IF	Citations
127	The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ: British Medical Journal, 2009, 339, b2700-b2700.	0.1	16,482
128	Alpha 1-Antitrypsin Deficiency. New England Journal of Medicine, 2009, 361, 2101-2102.	26.4	1
129	Informed choice requires information about both benefits and harms. Journal of Medical Ethics, 2009, 35, 268-269.	1.5	45
130	The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 2009, 6, e1000100.	4.6	15,857
131	Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Medical Research Methodology, 2009, 9, .	1.7	342
132	Mejorar la comunicación de estudios observacionales en epidemiología (STROBE): explicación y elaboración. Gaceta Sanitaria, 2009, 23, 158.e1-158.e28.	0.4	171
133	Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Women's Health, 2009, 9, .	1.7	83
134	Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. Journal of Negative Results in BioMedicine, 2009, 8, .	1.6	10
135	Readers as research detectives. Trials, 2009, 10, .	1.1	8
136	Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. Journal of Clinical Epidemiology, 2009, 62, 967-973.	2.5	47
137	The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology, 2009, 62, e1-e34.	2.5	10,195
138	Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. BMJ: British Medical Journal, 2009, 338, a3115-a3115.	0.1	333
139	Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. BMJ: British Medical Journal, 2009, 339, b3128-b3128.	0.1	74
140	A cause for celebration, and caution. BMJ: British Medical Journal, 2009, 338, b2126-b2126.	0.1	5
141	Fundamental errors in estimate of lives saved by screening. BMJ: British Medical Journal, 2009, 339, b3359-b3359.	0.1	3
142	Breast screening: the facts--or maybe not. BMJ: British Medical Journal, 2009, 338, b86-b86.	0.1	131
143	Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Medical Research Methodology, 2008, 8, .	1.7	315
144	Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions. BMC Medical Research Methodology, 2008, 8, .	1.7	67

#	Article	IF	Citations
145	Biases in estimates of overdetection due to mammography screening. Lancet Oncology, The, 2008, 9, 199-201.	16.1	15
146	Topical NSAIDs have unknown effectiveness. BMJ: British Medical Journal, 2008, 336, 344.3-344.	0.1	1
147	Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ: British Medical Journal, 2008, 337, a2299-a2299.	0.1	175
148	Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. International Journal of Epidemiology, 2007, 36, 847-857.	2.8	421
149	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Medicine, 2007, 4, e297.	4.6	5,413
150	Ghost Authorship in Industry-Initiated Randomised Trials. PLoS Medicine, 2007, 4, e19.	4.6	247
151	Data Extraction Errors in Meta-analyses That Use Standardized Mean Differences. JAMA - Journal of the American Medical Association, 2007, 298, .	14.4	184
152	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). Epidemiology, 2007, 18, 805-835.	2.0	2,623
153	Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. BMC Medicine, 2007, 5, .	4.4	45
154	Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ: British Medical Journal, 2006, 333, 231-234.	0.1	78
155	Were Patients With Unfavorable Outcomes Deleted in a Covert Duplicate Publication Reporting Effect of Placebo on Hypertension?. American Journal of Hypertension, 2006, 19, 655-655.	1.0	0
156	Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. Journal of Clinical Epidemiology, 2006, 59, 336-338.	2.5	40
157	Follow-up Commentary. Journal of Clinical Epidemiology, 2006, 59, 340-341.	2.5	1
158	Authors' reply on Cochrane reviews v industry supported meta-analyses. BMJ: British Medical Journal, 2006, 333, 1072.4-1073.	0.1	0
159	Laser and photoepilation for unwanted hair growth. The Cochrane Library, 2006, , .	1.7	68
160	Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials, 2006, 7, .	1.1	12
161	Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. BMC Medical Research Methodology, 2006, 6, .	1.7	3
162	Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. International Journal of Cancer, 2006, 118, 2648-2648.	2.8	2

#	Article	IF	Citations
163	Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ: British Medical Journal, 2006, 333, 782.	0.1	384
164	Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. European Journal of Cancer, 2006, , .	2.8	6
165	Ramifications of screening for breast cancer: Overdiagnosis in the Malmö trial was considerably underestimated. BMJ: British Medical Journal, 2006, 332, 727.2.	0.1	4
166	Human Albumin in Critically Ill Patients. Critical Care Medicine, 2005, 33, 1183.	0.5	4
167	The Journal Impact Factor as a Predictor of Trial Quality and Outcomes: Cohort Study of Hepatobiliary Randomized Clinical Trials. American Journal of Gastroenterology, 2005, 100, 2431-2435.	0.7	37
168	Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ: British Medical Journal, 2005, 330, 1049.	0.1	172
169	Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. The Cochrane Library, 2005, , .	1.7	57
170	Reduction in mortality from breast cancer. BMJ: British Medical Journal, 2005, 330, 1024.3.	0.1	1
171	Model of outcomes of screening mammography: Information needs to support informed choices. BMJ: British Medical Journal, 2005, 331, 350.3-351.	0.1	0
172	Re: Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2004, 96, 1257-1257.	3.2	5
173	Polyclonal Immunoglobulin for Treatment of Bacterial Sepsis: A Systematic Review. Clinical Infectious Diseases, 2004, 39, 38-46.	3.7	156
174	Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials. JAMA - Journal of the American Medical Association, 2004, 291, 2457.	14.4	1,665
175	Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. The Cochrane Library, 2004, , .	1.7	47
176	Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ: British Medical Journal, 2004, 328, 148-0.	0.1	124
177	On the benefits and harms of screening for breast cancer. International Journal of Epidemiology, 2004, 33, 56-64.	2.8	42
178	The debate on breast cancer screening with mammography is important. Journal of the American College of Radiology, 2004, 1, 8-14.	2.0	9
179	Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement. Annals of Internal Medicine, 2004, 141, 781-788.	7.3	1,392
180	Websites on screening for breast cancer:Authors' reply. BMJ: British Medical Journal, 2004, 328, 769.5.	0.1	0

#	Article	IF	Citations
181	Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain, 2003, 104, 714-715.	3.0	14
182	Regular self-examination or clinical examination for early detection of breast cancer. The Cochrane Library, 2003, , .	1.7	225
183	Screening for Breast Cancer. Annals of Internal Medicine, 2003, 138, 769-770.	7.3	1
184	Prevalence of Honorary and Ghost Authorship in Cochrane Reviews. JAMA - Journal of the American Medical Association, 2002, 287, 2769.	14.4	199
185	Trends in breast-conserving surgery in the Southeast Netherlands. European Journal of Cancer, 2002, 38, 1288.	2.8	8
186	Is the Placebo Powerless?. New England Journal of Medicine, 2001, 344, 1594-1602.	26.4	1,486
187	Cochrane review on screening for breast cancer with mammography. Lancet, The, 2001, 358, 1340-1342.	46.9	675
188	Quality of Cochrane reviews: assessment of sample from 1998. BMJ: British Medical Journal, 2001, 323, 829-832.	0.1	138
189	Debate on screening for breast cancer is not over. BMJ: British Medical Journal, 2001, 323, 693-693.	0.1	8
190	Is screening for breast cancer with mammography justifiable?. Lancet, The, 2000, 355, 129-134.	46.9	828
191	Extracts from "Clinical Evidence": Non-steroidal anti-inflammatory drugs. BMJ: British Medical Journal, 2000, 320, 1058-1061.	0.1	99
192	Randomised clinical trials in the Scandinavian Journal of Rheumatology. Scandinavian Journal of Rheumatology, 2000, 29, 349-351.	0.6	4
193	Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis. JAMA - Journal of the American Medical Association, 1999, 282, 1752.	14.4	112
194	Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ: British Medical Journal, 1998, 316, 811-818.	0.1	100
195	House dust mite control measures in the management of asthma: meta-analysis. BMJ: British Medical Journal, 1998, 317, 1105-1110.	0.1	189
196	Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ: British Medical Journal, 1998, 316, 1606-1606.	0.1	1
197	Alternating Treatment with Didanosine and Zidovudine versus Either Drug Alone for the Treatment of Advanced HIV Infection. The Alter Study. Scandinavian Journal of Infectious Diseases, 1997, 29, 121-128.	1.5	5
198	The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis. European Journal of Clinical Pharmacology, 1997, 51, 389-393.	1.6	41

#	Article	IF	Citations
199	Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ: British Medical Journal, 1997, 314, 1238.	0.1	101
200	Blinding during data analysis and writing of manuscripts. Contemporary Clinical Trials, 1996, 17, 285-290.	2.8	117
201	Guidelines for treatment of hypertension. Lancet, The, 1995, 346, 1631.	46.9	1
202	Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ: British Medical Journal, 1995, 310, 1495-1498.	0.1	67
203	Steroids and peptic ulcer: an end to the controversy?. Journal of Internal Medicine, 1994, 236, 599-601.	4.0	16
204	Meta-analysis of NSAIDs: Contribution of Drugs, Doses, Trial Designs, and Meta-analytic Techniques. Scandinavian Journal of Rheumatology, 1993, 22, 255-260.	0.6	21
205	Cimetidine suspension as adjuvant to energy restricted diet in treating obesity.. BMJ: British Medical Journal, 1993, 306, 1093-1096.	0.1	23
206	Cimetidine and weight loss. BMJ: British Medical Journal, 1993, 307, 446.4-447.	0.1	0
207	Trend towards Decreased Survival in Patients Infected with HIV Resistant to Zidovudine. Scandinavian Journal of Infectious Diseases, 1992, 24, 563-565.	1.5	5
208	Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. Journal of Clinical Epidemiology, 1992, 45, 587-594.	2.5	23
209	Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. Antiviral Research, 1992, 18, 303-316.	2.7	12
210	Isolation of HIV from cultures of purified CD4+ lymphocytes. Journal of Virological Methods, 1991, 35, 15-25.	1.0	14
211	Patients' views on the least acceptable increase in survival with zidovudine treatment. Scandinavian Journal of Infectious Diseases, 1991, 23, 509-510.	1.5	3
212	Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials controlled NSAID trials. Journal of Clinical Epidemiology, 1990, 43, 1313-1318.	2.5	82
213	Multiple publication of reports of drug trials. European Journal of Clinical Pharmacology, 1989, 36, 429-432.	1.6	99
214	PATIENTS' PREFERENCE IN INDOMETHACIN TRIALS: AN OVERVIEW. Lancet, The, 1989, 333, 88-91.	46.9	32
215	Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Contemporary Clinical Trials, 1989, 10, 31-56.	2.8	302
216	Double-Blind Study of Naproxen vs Placebo in the Treatment of Acute Migraine Attacks. Cephalalgia, 1989, 9, 29-32.	2.7	22

#	Article	IF	Citations
217	Steady State Pharmacokinetics of Naproxen in Elderly Rheumatics Compared with Young Volunteers. Scandinavian Journal of Rheumatology, 1988, 17, 11-16.	0.6	12
218	Condoms to Prevent HIV Transmission Do Not Imply Truly Safe Sex. Scandinavian Journal of Infectious Diseases, 1988, 20, 233-234.	1.5	18
219	Yield of Diagnostic Tests for Opportunistic Infections in AIDS: A Survey of 33 Patients. Scandinavian Journal of Infectious Diseases, 1988, 20, 395-402.	1.5	7
220	Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. BMJ: British Medical Journal, 1988, 296, 820-822.	0.1	36
221	Reference bias in reports of drug trials.. BMJ: British Medical Journal, 1987, 295, 654-656.	0.1	188
222	A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. International Journal of Oral and Maxillofacial Surgery, 1986, 15, 389-394.	1.4	23
223	Somatostatin analogues for acute bleeding oesophageal varices. The Cochrane Library, 0, 2012, .	1.7	63
224	Placebo interventions for all clinical conditions. The Cochrane Library, 0, , .	1.7	411
225	General health checks in adults for reducing morbidity and mortality from disease. The Cochrane Library, 0, , .	1.7	186
226	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. The Cochrane Library, 0, , .	1.7	12
227	“Adaptive pathways” to drug authorisation: adapting to industry?. BMJ, The, 0, , i4437.	0.2	43
228	Screening for reducing morbidity and mortality in malignant melanoma. The Cochrane Library, 0, , .	1.7	3
229	Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ, The, 0, , i65.	0.2	269
230	Antidepressants are addictive and increase the risk of relapse. BMJ, The, 0, , i574.	0.2	4
231	Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane Library, 0, , .	1.7	5
232	Financial conflicts of interest and outcomes and quality of systematic reviews. The Cochrane Library, 0, , .	1.7	5
233	Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ: British Medical Journal, 0, , k3654.	0.1	58
234	Challenges of independent assessment of potential harms of HPV vaccines. BMJ: British Medical Journal, 0, , k3694.	0.1	15

#	Article	IF	Citations
235	Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. BMJ: British Medical Journal, 0, 323, 1131.2.	0.1	0